Evaluate the use of nasal mucosal autonomic nerve responses as an objective indicator for assessing the efficacy of vidian neurectomy (VN) in treating allergic rhinitis (AR) Respiratory
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with moderate to severe AR without age limitation 2. Selection adhered to the ARIA guidelines, which require AR symptoms to persist for over 4 weeks, occurring more than 4 days per week and lasting longer than 4 hours each day 3. Candidates were either unresponsive to conventional drug treatments or exhibited intolerance
Exclusion criteria
Exclusion criteria: 1. Any nasal surgeries within the 6 months before the study 2. Pregnancy or lactating 3. Prior medical history or conditions that could influence autonomic nerve function or inflammatory responses, such as severe cardiovascular diseases, neurological disorders or other types of rhinitis 4. A history of autoimmune disorders, such as rheumatoid arthritis 5. Use of medications affecting the autonomic nervous system within the last 3 months, such as beta-blockers or immunosuppressants
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Waveform of nasal mucosal autonomic responses and sympathetic skin response measured using waveforms and amplitude of electrical signals before and 1 month after the patients underwent low-temperature plasma VN | — |
Secondary
| Measure | Time frame |
|---|---|
| The effect of comorbidities (nasal polyps, sinusitis and a deviated nasal septum) on surgery efficacy measured using the amplitude of autonomic nervous responses in the left and right nasal mucosa of patients with three types of comorbidities before and 1 month after the patients underwent low-temperature plasma VN | — |
Countries
China